Combination Therapy for BPH: When and Why (Alpha-Blocker + 5-ARI)

What is combination therapy for BPH?

Combination therapy for BPH refers to the simultaneous use of two different classes of medications:

• An alpha-blocker (tamsulosin, alfuzosin, silodosin, doxazosin, terazosin) – relaxes smooth muscle in the prostate and bladder neck for rapid symptom relief.
• A 5-alpha reductase inhibitor (5-ARI) (finasteride, dutasteride) – shrinks the prostate by lowering DHT levels for long-term benefits.

Why combine medications?

Alpha-blockers and 5-ARIs work through completely different mechanisms, making them complementary:

• Alpha-blockers: Target dynamic obstruction (muscle tone). Work rapidly (days to weeks). Do not shrink the prostate. Do not reduce long-term complications.
• 5-ARIs: Target static obstruction (prostate size). Work slowly (3-6 months). Shrink the prostate. Reduce risk of acute urinary retention and need for surgery.

By combining them, patients get:

• Rapid symptom relief from the alpha-blocker
• Long-term disease modification from the 5-ARI
• Greater overall symptom improvement than either alone
• Reduced risk of BPH progression (acute retention, surgery)

Who needs combination therapy?

Combination therapy is NOT for every man with BPH. Ideal candidates:

• Prostate size >40 mL (measured by ultrasound or DRE) – 5-ARIs are ineffective in small prostates
• Moderate to severe symptoms (IPSS ≥8) that affect quality of life
• Willing to take daily medication long-term
• At risk for BPH progression – high PSA, large prostate, older age, high post-void residual

Who does NOT need combination therapy:

• Men with small prostates (<30 mL) – 5-ARI adds little benefit
• Men with mild symptoms (IPSS <8) who are not bothered
• Men who cannot tolerate sexual side effects (ED, decreased libido)
• Men planning to father children (5-ARIs affect sperm)

Evidence from the MTOPS study

The landmark MTOPS (Medical Therapy of Prostatic Symptoms) trial, published in 2003, established combination therapy as the gold standard for men with larger prostates.

Study design:

• Over 3,000 men with BPH followed for 4-6 years
• Randomised to: placebo, doxazosin (alpha-blocker) alone, finasteride (5-ARI) alone, or combination (doxazosin + finasteride)
• Primary endpoint: clinical progression (IPSS rise ≥4, acute urinary retention, incontinence, or surgery)

Key results:

• Combination therapy reduced risk of clinical progression by 66% compared to placebo
• Doxazosin alone: 39% reduction
• Finasteride alone: 34% reduction
• Combination was significantly better than either alone
• Combination reduced the risk of acute urinary retention by 67% and need for surgery by 64%

Benefits of combination therapy

• Superior symptom improvement: IPSS reduction 5-7 points (vs. 3-5 points for monotherapy)
• Faster onset: Alpha-blocker provides relief within days while waiting for 5-ARI to work
• Greater peak flow (Qmax) improvement: 2.5-3.5 mL/s vs. 1.5-2.0 mL/s for monotherapy
• Prostate shrinkage: 20-30% reduction in prostate volume
• Reduced risk of acute urinary retention: 60-70% reduction
• Reduced need for BPH surgery (TURP/HoLEP): 60-70% reduction
• Slower symptom progression: Delays need for escalation to surgery

Risks and side effects

Combination therapy carries the side effects of both drug classes. Not additive (side effects are similar to monotherapy rates), but patients may experience side effects from either drug:

Alpha-blocker side effects (tamsulosin, etc.):

• Retrograde ejaculation (2-30% depending on agent)
• Dizziness, orthostatic hypotension (especially doxazosin/terazosin)
• Nasal congestion (5-10%)

5-ARI side effects (finasteride, dutasteride):

• Erectile dysfunction (4-7%)
• Decreased libido (3-6%)
• Reduced ejaculate volume (1-2%)
• Gynecomastia (breast tenderness/enlargement – 1-2%)

Important considerations:

• Side effects are generally mild and reversible upon stopping
• Not all patients experience side effects (most tolerate well)
• Choosing specific agents can minimise certain side effects (e.g., alfuzosin for lower retrograde ejaculation)

When to start combination therapy

Guidelines recommend combination therapy for men who meet ALL of the following:

• Moderate to severe symptoms (IPSS ≥8)
• Prostate size >40 mL (or PSA >1.5 ng/mL as a surrogate for size)
• Bothersome symptoms affecting quality of life
• At risk for BPH progression (older age, high PSA, high post-void residual)

Practical approach:

• Start with alpha-blocker monotherapy for rapid relief
• Add 5-ARI if prostate is >40 mL and patient wants long-term risk reduction
• Alternatively, start both together if patient has large prostate and significant symptoms

When to stop or switch

Consider discontinuing combination therapy if:

• No symptom improvement after 6-9 months – consider alternative therapy
• Intolerable side effects – switch to monotherapy or different agents
• Developed complications (acute retention, recurrent UTIs) – may need surgery
• Patient preference – some men prefer to stop medications after symptom improvement

Switching options:

• If sexual side effects from 5-ARI: stop 5-ARI, continue alpha-blocker
• If retrograde ejaculation from alpha-blocker: switch to alfuzosin (lower rate) or stop alpha-blocker (if 5-ARI has taken effect)
• If poor response: consider minimally invasive BPH treatment (Rezum, UroLift) or surgery (TURP, HoLEP)

Alternatives to combination therapy

• Alpha-blocker monotherapy: For small prostates (<30 mL) or men who cannot tolerate 5-ARI side effects
• 5-ARI monotherapy: For large prostates but mild symptoms; slower onset, no rapid relief
• Minimally invasive procedures: Rezum, UroLift, TUMT – good for men who want to avoid daily medications
• Surgery (TURP, HoLEP): For men with severe symptoms, large prostates, or complications
• Watchful waiting: For men with mild symptoms not affecting quality of life

Comparison: Monotherapy vs. combination therapy

Feature	Alpha-Blocker Alone	5-ARI Alone	Combination Therapy
Onset of action	Days	3-6 months	Days (alpha) + months (5-ARI)
IPSS reduction	30-40%	15-25%	40-50%
Peak flow (Qmax) increase	1.5-2.5 mL/s	1.5-2.0 mL/s	2.5-3.5 mL/s
Prostate size reduction	None	20-30%	20-30%
Risk reduction for AUR/surgery	None	50-60%	60-70%
Side effects	Retrograde ejaculation, dizziness	ED, ↓ libido	Both classes (not additive)

Interactive FAQ – Combination therapy for BPH

---

Disclaimer: This information is for educational purposes. Combination therapy is a prescription treatment. Discuss risks, benefits, and alternatives with a urologist at Vivekananda Hospital.